Urigen Pharmaceuticals and Oceana Therapeutics jointly prepare for meeting with FDA on URG101

Urigen Pharmaceuticals, Inc. (OTCBB:URGP), a specialty pharmaceutical company focused on the development of treatments for urological disorders and pain, announced today that the Company and Oceana Therapeutics have agreed to jointly prepare for a meeting with the U.S. Food & Drug Administration regarding the continued development of URG101.

“Oceana has expertise in developing and commercializing drugs which are delivered procedurally, including in urology”

"Oceana has expertise in developing and commercializing drugs which are delivered procedurally, including in urology," said Urigen’s CEO William J. Garner, MD. “This allows Urigen to move URG101 forward with a talented potential partner to prepare for an FDA meeting.” David S. Tierney, M.D., President and COO, Oceana Therapeutics, said, “We’re excited about the potential of URG101, there is clearly an unmet medical need in Painful Bladder Syndrome/Interstitial Cystitis.”